Russia's Oncopept and Neooncovac: Unverified Domestic Cancer Vaccine Claims

In late 2025 and early 2026, Russian state-affiliated institutions announced two cancer-vaccine programs: Oncopept, a colorectal cancer vaccine approved by the FMBA (Federal Medical-Biological Agency) in November 2025, and Neooncovac, an mRNA cancer vaccine that first-dosed a patient in April 2026. The research consortium comprises Russia's three highest-profile biomedical centers: the Gamaleya Research Institute (the developer of Sputnik V), the National Medical Research Radiological Center (NMRRC), and the Blokhin National Medical Research Center of Oncology. State media described the vaccines as personalized, neoantigen-based, and free at the point of care. What is missing is the validation infrastructure that defines a credible drug claim. No peer-reviewed publication in a Western or independent journal has documented the trial design, patient selection, primary endpoints, response rates, or safety profile. Independent oncology and immunology experts who reviewed publicly released information have noted that the preclinical animal data appears to overstate the magnitude of tumor-clearance effects observed. This pattern is not unique to cancer. Sputnik V, also from Gamaleya, generated political controversy partly because early efficacy claims preceded peer-reviewed publication in The Lancet by months. Domestic Russian regulatory approval through FMBA does not subject products to the same scrutiny as FDA, EMA, or PMDA review. Until trial data is published in a journal with international peer review and ideally replicated by independent groups, Oncopept and Neooncovac should be treated as promising-but-unverified rather than as approved cancer treatments comparable to Dostarlimab, Nous-209, or other peer-reviewed programs.